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Abstract
 
Previous studies in mice and humans have suggested an important role for CD8
 
 
 
 T cells in host
defense to Mtb. Recently, we have described human, Mtb-specific CD8
 
 
 
 cells that are neither
HLA-A, B, or C nor group 1 CD1 restricted, and have found that these cells comprise the
dominant CD8
 
 
 
 T cell response in latently infected individuals. In this report, three indepen-
dent methods are used to demonstrate the ability of these cells to recognize Mtb-derived anti-
gen in the context of the monomorphic HLA-E molecule. This is the first demonstration of
the ability of HLA-E to present pathogen-derived antigen. Further definition of the HLA-E
specific response may aid development of an effective vaccine against tuberculosis.
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Introduction
 
CD8
 
 
 
 T Cells in the Host Response to Tuberculosis. My-
cobacterium tuberculosis
 
 (Mtb)
 
*
 
, the etiological agent of tuber-
culosis (TB), remains a leading cause of infectious disease
morbidity and mortality worldwide, with WHO (1) esti-
mates of 8.4 million TB cases and two million TB-related
deaths in 1999. In spite of these sobering statistics, the host
cellular immune response successfully contains 90% of Mtb
infections. Without doubt, HLA-II–mediated recognition
of Mtb-derived antigens plays an essential role in the host
response, due at least in part to the release of proinflamma-
tory cytokines such as IFN-
 
 
 
 and TNF-
 
 
 
, and the subse-
quent activation of macrophages (2, 3).
While CD4
 
 
 
 T lymphocytes are essential for the con-
tainment of mycobacterial infection, there is increasing ev-
idence to suggest that they are not sufficient. First, mice
deficient in 
 
 
 
2M, and hence MHC class I–dependent
immunity, are impaired in their ability to control infection
(4, 5). These observations are corroborated by data ob-
tained in mice deficient in transporter associated with anti-
gen processing (TAP), and hence MHC class I antigen pro-
cessing (6). Second, activation of human macrophages by
CD4-derived cytokines such as IFN-
 
 
 
 and TNF-
 
 
 
 results
in only modest containment of Mtb growth in vitro, due in
part to a relative deficiency of inducible nitrous oxide.
Third, granulysin, a constituent of the CTL granule has a
direct mycobacteriostatic effect (7).
To explore the role of human CD8
 
 
 
 T cells in the host
response to TB, we have used Mtb-infected dendritic
cells (DCs) to derive both classically and nonclassically
HLA-restricted CD8
 
 
 
 T cell clones from a latently in-
fected individual (8, 9). Using a modified LDA analysis
with Mtb-infected DCs as the APC, these nonclassically
restricted clones were found to comprise the majority of
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Mtb-specific CD8
 
 
 
 T cells in two latently infected sub-
jects (9).
 
Nonclassically Restricted CD8
 
 
 
 T Cells in the Host Response
to TB.
 
Classical or HLA-Ia restricted CTL are defined as
those restricted by the polymorphic MHC molecules
HLA-A, B, and C. HLA-Ia–restricted T cells are capable of
recognizing peptide antigens processed and presented from
Mtb-infected APCs (2). Additionally, the effector cell fre-
quencies to some Mtb proteins such as Ag85, 19 kD,
ESAT-6, and CFP10/Mtb11 would suggest that these re-
sponses represent a robust recall response to mycobacterial
infection (10–13).
Nonclassical or HLA-Ib–restricted CTL are defined as
those restricted by monomorphic molecules with sequence
homology to the classical HLA-Ia molecules. By presenting
molecules uniquely derived from a bacterial source, these
molecules may bridge traditional definitions of innate and
acquired immunity. Examples include (i) the human group
1 CD1 (CD1a, b, and c) molecules, that process and
present mycobacterially derived lipid and glycolipid anti-
gens by virtue of an unusually deep-binding pocket (14),
(ii) the murine H2M3 molecule which presents short, bac-
terially derived peptides possessing an NH
 
2
 
 terminal,
formyl-methionine (15, 16), and (iii) the murine Qa1 mol-
ecule that can present GroEL-derived peptides from 
 
Salmo-
nella 
 
(17, 18). The importance of nonclassically restricted T
cells in the host response to infection with Mtb remains
poorly defined, although it is intriguing that mice deficient
in MHC class Ia molecules (H2-K
 
b
 
/H2-D
 
b
 
 double knock-
out mice) were better able to control infection than those
deficient in 
 
 
 
2M (MHC-Ia and MHC-Ib deficient, refer-
ence 19). Our data showing that nonclassically restricted T
cells comprised the majority of Mtb-specific CD8
 
 
 
 T cells
in two latently infected subjects suggested that this subset of
T cells plays a significant role in the human host response
to infection with Mtb. Two nonclassically restricted clones
have been extensively characterized. These clones (23, 29)
responded to APCs infected with the closely related Mtb
and 
 
Mycobacterium bovis
 
 species, but not to atypical myco-
bacteria such as 
 
Mycobacterium
 
 
 
avium
 
. While phenotypically
similar to other antigen-specific CD8
 
 
 
 T cell clones
(CD8
 
 
 
, 
 
  
 
 TCR
 
 
 
, negative for NK cell markers CD16
and CD56), these clones were neither HLA-A, B, or C nor
CD1 restricted. Studies with anti–HLA-I– and –HLA-II–
blocking antibodies showed partial blockade with the pan–
HLA-I antibody W6/32, but not with anti–HLA-II or
anti–HLA-A antibodies. Mtb-derived antigen presentation
was found to require proteasomal processing, but to be pre-
sented in a manner that was Brefeldin and hence TAP in-
dependent (8). In this work, we define HLA-E as the re-
stricting allele for the nonclassically restricted clones.
 
Materials and Methods
 
Human Subjects.
 
Subjects were recruited from employees at
Harborview Medical Center, Seattle, WA and Oregon Health
Sciences University, Portland, OR. Protocols for venipuncture
 
and apheresis have been IRB approved. The T cell clones studied
herein were derived from a single latently infected individual
(D160, documented TST conversion, no evidence of active dis-
ease, HLA-A2, A3, B14, B44).
 
Media and Reagents.
 
Culture medium consisted of RPMI
1640 supplemented with 10% Serva (Bio Whittaker), 50 
 
 
 
g/ml
gentamicin sulfate (Bio Whittaker), 5 
 
 
 
 10
 
 
 
5 
 
M 2 ME (Sigma-
Aldrich), and 2 mM glutamine (GIBCO BRL). For the growth
and assay of Mtb-reactive T cell clones, RPMI 1640 was supple-
mented with 10% human serum. Mtb strain H37Rv was ob-
tained from American Type Culture Collection and grown in
modified Middlebrook 7H9 media (Difco). After the preparation
of glycerol stocks, aliquots were frozen, and subsequently titered
on Middlebrook 7H10 plates (Becton Dickinson). H37Rv man-
nose lipoarabinomannan, Triton X-114 lipoprotein/membrane
protein fraction (TX-114), culture filtrate proteins (CFPs), cell
wall fraction, cell membrane fraction, cytosol fraction, mycolylar-
abinogalactan peptidoglycan, or Mtb genomic DNA were pro-
vided through NIAID contract N01 AI-75320 and Colorado
State University, Fort Collins, CO.
 
Cell Lines and T Cell Clones.
 
EBV-transformed B cell lines
were generated in our laboratory using supernatants from the cell line
9B5–8 (American Type Culture Collection). In the experiments pre-
sented herein, LCL were from HLA-A2 positive donors (D160 &
KA). The HLA-I–deficient LCL line 721.221 as well as transfectants
expressing HLA-E (721.221 E), HLA-E that is expressed with the
HLA-A2 leader peptide required for cell surface expression (721.221
AEH), and HLA-F (721.221 F) were provided by D. Geraghty, Fred
Hutchinson Cancer Research Center, Seattle, WA (20). 721.221
transfectants were cultured in the presence of hygromycin B (Calbio-
chem) in the medium at 200 mU/ml. HLA-A and -B null C1R
transfectants expressing group 1 CD1 antigens were provided by W.
Storkus, University of Pittsburgh Medical Center and University of
Pittsburgh Cancer Institute, Pittsburgh, PA. CD1 transfectants of
C1R were maintained in medium containing 1.8 mg/ml G418
(Genetecin, GIBCO BRL) as described previously (21). Cell lines
were maintained by continuous passage in RPMI 1640 culture me-
dium supplemented with 10% FBS. The TAP-deficient cell line T2-
and 
 
 
 
2m-deficient cell line Daudi were obtained from American
Type Culture Collection.
Clones 23, 29, and 1–1B were derived from the same latently
infected individual using Mtb-infected DCs as APCs. Clone
1–1B, is an Mtb CPF10/Mtb11 specific CD8
 
 
 
 T cell clone that
is HLA-44 restricted and responds to the cognate peptide
AEMKTDAATL (AA 2–11; reference 13).
 
Expansion of T Cell Clones.
 
To expand the CD8
 
 
 
 T cell clones,
a rapid expansion protocol using anti-CD3 mAb stimulation was used
(22). T cell clones were cultured in the presence of irradiated alloge-
neic PBMCs (25 
 
  
 
10
 
6
 
), irradiated allogeneic LCL (5 
 
  
 
10
 
6
 
), and
anti-CD3 mAb (30 ng/ml; Chiron) in RPMI 1640 media with 10%
human serum in a T-25 upright flask in a total volume of 30 ml. The
cultures were supplemented with IL-2 (1 ng/ml; Chiron) on days
 
 
 
1, 
 
 
 
4, 
 
 
 
7, and 
 
 
 
10 of culture. The cell cultures were washed on
day 
 
 
 
4 to remove remaining soluble anti-CD3 mAb.
 
Generation of Peripheral Blood DCs and Macrophages.
 
Monocyte-
derived DCs were prepared according to the method of Romani
et al. (23). In brief, PBMCs were isolated from heparinized blood
by centrifugation over Ficoll-Hypaque (Sigma-Aldrich) and
washed three times with culture medium. Alternatively, PBMCs
were obtained via leukapheresis. Cells were resuspended in 1%
HS medium and allowed to adhere to a T-75 (Costar) flask at 37
 
 
 
for 1 h in the presence of 10 ng/ml of GM-CSF (Immunex
Corp.). After gentle rocking, nonadherent cells were removed, 
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and 30 ml of 10% HS medium containing 10 ng/ml of IL-4 (Im-
munex Corp.) and 30 ng/ml of GM-CSF (Immunex Corp.) was
added. After 18 h, the media was removed, centrifuged, and the cell-
conditioned media placed on the adherent cells. After 5–7 d, cells were
harvested with cell-dissociation media (Sigma-Aldrich).
 
Mtb/DC-conditioned Media.
 
10
 
6
 
 monocyte-derived DCs were
cultured overnight in the presence of Mtb (H37Rv; MOI 
 
 
 
 100)
in low-adherence 16-mm wells (model no. 3473, Costar). After
18 h, supernatants were harvested and passed through a 0.2 
 
 
 
M
filter (Gelman Sciences) to remove viable Mtb. Where indicated,
conditioned media was treated with either lipase (3,000 U/ml;
Sigma-Aldrich L-8525), DNase (2 U/ml; Sigma-Aldrich D5793),
or proteinase K (0.2 mg/ml; Sigma-Aldrich P-0390). After over-
night incubation, PMSF (60 
 
 
 
g/ml, Sigma-Aldrich) was added to
all samples to inactivate proteinase K and to control for PMSF
toxicity. To determine whether or not proteasomal function is
required for the generation of the peptide antigen, DCs were in-
cubated with lactacystin either before or 18 h after the addition of
Mtb. To assay the activity of the supernatant, DCs were seeded at
5 
 
 
 
 10
 
4
 
 cells per well in 96-well, flat-bottomed plates in 50 
 
 
 
l of
media. 5 
 
 
 
 10
 
4
 
 T cells in 50 
 
 
 
l of media and 100 
 
 
 
l of condi-
tioned media were then added, and IFN-
 
 
 
 assayed by ELISA af-
ter 18 h incubation at 37
 
 
 
C.
 
Flow Cytometry.
 
Cells to be analyzed for cell surface marker
expression were first incubated at 4
 
 
 
C in a blocking solution of
PBS containing 2% normal rabbit serum (Sigma-Aldrich), 2%
normal goat serum (Sigma-Aldrich), and 2% human serum to
prevent nonspecific binding of mouse Ig. Cells were washed in
FACS
 
®
 
 buffer (PBS containing 0.5% FBS and 0.02% sodium
azide) and incubated with either anti–HLA-E 3D12 (5 
 
 
 
g/ml;
reference 21), anti–HLA-A2, anti–HLA-DR, or isotype control
(5 
 
 
 
g/ml, Becton Dickinson) for 30 min at 4
 
 
 
C in a total volume
of 50 
 
 
 
l. Cells were then washed, stained with an anti–mouse
FITC antibody (Becton Dickinson) for 30 min at 4
 
 
 
C, and after
washing, flow cytometry was performed using a FACSCalibur™
(Becton Dickinson). Data were collected on 10
 
4
 
 viable cells.
 
IFN-
 
 
 
 ELISPOT Assay.
 
Mtb-specific effectors were de-
tected from purified CD8
 
 
 
 T cells by ELISPOT, as described
with minor modifications (24). In brief, 96-well nitrocellulose-
backed plates (MAHA S4510; Millipore) were coated as recom-
mended by the manufacturer with 10 
 
 
 
g/ml capture mouse
anti-IFN (1-D1K, Mabtech AB) overnight at 4
 
 
 
C. Plates were
then washed six times with PBS/0.05% Tween 20 (Sigma-
Aldrich), blocked with RPMI 1640/10% HS for 1 h at room
temperature. T cell clones (200) and APC (20,000) are added,
and the plate incubated overnight at 37
 
 
 
C. After washing with
PBS/0.05% Tween 20, 100 
 
 
 
l of 1 
 
 
 
g/ml biotinylated second-
ary anti–IFN-
 
 
 
 mAb (7B6–1, Mabtech AB) was added. After 2 h
of incubation at room temperature, plates were washed six times
and 100 
 
 
 
l Avidin/Biotinylated Enzyme (HRP) Complex
(Vectastain ABC Elite kit; Vector Laboratories) was added to
wells, and the plates were incubated for a further 1 h. Then,
plates were washed six times, and 100 
 
 
 
l AEC substrate
(Vectastain AEC substrate kit; Vector Laboratories) was added.
After 4–7 min, the colorimetric reaction was stopped by wash-
ing with distilled water. Spots were quantitated using a Zeiss
Axioplan 2 microscope with 3,200 K incident illumination
equipped with a Epiplan Neofluar 5
 
 
 
/0.15 objective, Sony
DXC 950 CCD camera, Märzhäuser scanning stage, MCP4
control unit, Pentium PC computer, and KS ELISPOT software
(Carl Zeiss Vision).
 
Adenovirus Infection of APC.
 
To generate adenovirally in-
fected APCs, DCs were harvested after 18 h of culture, and 5 
 
 
 
10
 
5
 
 DCs were seeded in Optimem (125 
 
 
 
l; Gibco Invitrogen
Corp.) into low-adherence 16-mm wells (Costar). Adenoviral li-
posomes were prepared by coincubating the adenovirus and lipo-
fectamine (6 
 
 
 
g/ml; Gibco Invitrogen Corp.) for 15 min and
then added to the DC cultures. After 4–6 h, 1 ml fresh media
containing GM-CSF (10 ng/ml; Immunex Corp.) and IL-4 (10
ng/ml; Immunex Corp.) was added.
 
Preparation and Manipulation of Triton X-114 Soluble Proteins.
 
Mtb H37Rv cells were disrupted by French press in a buffer of 10
mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, and 4%
Triton X-114. The lysate was rocked overnight at 4
 
 
 
C, followed
by centrifugation at 27,000
 
  
 
g
 
 (4
 
 
 
C) for 1 h. The supernatant
was collected and placed at 37
 
 
 
C for 40 min to allow for biphasic
partitioning and centrifuged at 27,000  g (20 C) for 30 min. The
aqueous phase was removed and the detergent phase was back ex-
tracted three times with 10 mM Tris-HCl, pH 7.4, 150 mM
NaCl, and 1 mM EDTA (25). Precipitation of proteins from the
final aqueous phase was achieved by the addition of 10 vol cold
acetone and centrifugation at 27,000  g. The protein pellet was
suspended in PBS, pH 7.5. To remove glycans and lipoglycans
from the TX-114 protein extract, an equal vol of PBS saturated
phenol was added to the protein suspension and rocked at room
temperature for 2 h, followed by centrifugation at 27,000  g for
30 min. The aqueous phase was removed, and the phenol phase
and interface was back extracted three times with an equal vol of
PBS, pH 7.5. The final phenol phase was dialyzed extensively
(2–3 d) against H20, and the protein concentration was deter-
mined using the bicinchoninic acid assay (26). 1 mg aliquots of
the TX-114 soluble protein pool were digested with 10  g/ml
pronase at 37 C for 18 h. The removal of lipophilic material from
the pronase digested sample was achieved by organic extraction
with CHCl3/CH3OH 2:1 (27).
Statistical Analysis. Where indicated, error bars denote the
SEM of the mean. To compare each experimental mean with the
control mean the “Dunnett’s test” was employed. Statistical analy-
sis performed using JMP software (SAS Institute Inc., Cary, NC).
Results
Mtb-derived Antigen Is Present in Mtb/DC-conditioned Me-
dia. Recent analysis of the Mtb-derived 19-kD lipoprotein
has demonstrated that presentation to HLA-Ia–restricted T
cells can occur in a proteasome-dependent, but TAP-inde-
pendent fashion using a paracrine-processing mechanism
by which Mtb-derived lipopeptides gain access to an early
endosomal compartment and are then potentially exported
in a lipid vesicle (28, 29). This pathway would be consis-
tent with the proteasome-dependent, TAP-independent
pathway that we had observed, and led to the speculation
that Mtb-derived antigen would be found within media
conditioned by Mtb-infected DCs.
To test this hypothesis, human DCs were infected over-
night with Mtb (H37Rv; MOI   50), and the resulting su-
pernatants twice filtered through a 0.2-  filter to remove via-
ble bacteria. These supernatants were then used to sensitize
fresh DCs, and reactivity of the nonclassical CD8  clones as-
sessed by IFN-  release. Mtb/DC-conditioned media was
able to elicit T cell–dependent cytokine release (Fig. 1 a).
Previously, we demonstrated that treatment of DCs with
Escherichia coli, Staphylococcus aureus, LPS, or atypical myco-1476 HLA-E and Host Response to TB
bacteria could not elicit IFN-  release from the nonclassi-
cally restricted clones (8), arguing against a nonspecific ef-
fect of DC activation. Here we have undertaken a series of
experiments to further validate the relationship of naturally
processed and presented Mtb antigen and the activity seen
in the Mtb/DC supernatants. First, Mtb/DC supernatants
were treated with either proteinase K, DNase, or lipase.
Proteinase K abolished the ability of the supernatants to
sensitize fresh DCs (Fig. 1 b), whereas lipase and DNase
had no effect. Then, we sought to determine whether or
not antigen processing was required for supernatant activ-
ity. Prior experiments were performed with fixed DCs,
eliminating any possible effect of residual inhibitor on T
cell activation. Previously, we have found that overnight
incubation with lactacystin did not interfere with the ability
to process and present HLA-II–associated antigen (8), and
have found that HLA-Ia–dependent presentation of pep-
tide antigen is not impaired (unpublished data). Because the
supernatants would also contain the inhibitor, the proteaso-
mal blocker lactacystin was added either before or after
Mtb infection to control for possible toxicity. Lactacystin
added before but not after infection with Mtb abolished
antigenic activity (Fig. 1 c). These data suggested that pro-
teasomal processing was required for the antigenic activity
seen in the Mtb/DC supernatants.
HLA-E–dependent Antigen Presentation. Previously, we
had found that the pan–HLA-I antibody W6/32 could
partially inhibit the recognition of Mtb-infected DCs by
the nonclassical clones (8). These data were consistent
with the hypothesis than an HLA-Ib molecule might re-
strict the nonclassical T cells. In this regard, W6/32 is ca-
pable of binding to HLA-E, F, and G in addition to classi-
cal HLA. HLA-E is known to bind HLA-Ia leader
peptides, and to serve as an NK inhibitory molecule
through its interaction with the CD94/NKG2A het-
erodimer (30, 31). However, several pieces of data sug-
gested that it could also serve to directly present antigen to
CD8  T cells. First, Martinozzi and colleagues demon-
strated that mouse CD8  T cells can recognize HLA-A2
leader peptide in the context of HLA-E (32). Second, re-
combinant HLA-E is capable of binding to peptides from
a combinatorial peptide library distinct from the known
HLA-Ia leader peptides (33). Finally, HLA-I and virus-
derived peptides can be recognized by human NK-like
   TCR, CD8  T cell clones in the context of HLA-E
(34, 35). While these studies demonstrate the ability of T
cells to recognize peptide presented in the context of
HLA-E, the physiological relevance of this observation
remains unknown.
To test the hypothesis that the Mtb-specific nonclassical
T cells were restricted by HLA-E, we sought to determine
Figure 1. Mtb-derived antigen in Mtb/DC-conditioned media. (A) To
assay the activity of the supernatant, DCs were seeded at 5   104 cells per
well in 96-well, flat-bottomed plates in 50  l of media. 5   104 T cells in
50  l of media and 100  l of conditioned media were then added, and
IFN-  assayed by ELISA after 18 h incubation at 37 C. Results represent
the mean of duplicate determinations. Error bars denote the SEM. *P  
0.05, where the “Dunnett’s test” has been used to compare each experi-
mental mean with the control mean (T plus Control DC Supe). This ex-
periment is representative of three such experiments. (B) Where indi-
cated, Mtb/DC-conditioned media was treated with either lipase (3,000
U/ml L-8525, Sigma-Aldrich), DNase (2 U/ml D5793, Sigma-Aldrich),
or proteinase K (0.2 mg/ml P-0390, Sigma-Aldrich). After overnight in-
cubation, PMSF (60  g/ml; Sigma-Aldrich) was added to all samples to
inactivate the proteinase K. Results represent the mean of duplicate deter-
minations. Error bars denote the SEM. Asterisks denote a significant loss
of antigenic activity (P   0.05) where the “Dunnett’s test” has been used
to compare each experimental mean with the control mean (No Treat-
ment). This experiment is representative of two such experiments. (C) To
determine whether or not proteasomal function is required for the gener-
ation of the peptide antigen, DCs were incubated with lactacystin (40
 M; E.J. Corey; Harvard Biolabs, Harvard, MA) added either before or
18 h after the addition of Mtb. T cell–dependent IFN-  release was assessed
as described in A. Results represent the mean of duplicate determinations.
Error bars denote the SEM. Asterisks denote significant inhibition of anti-
genic activity (P   0.05) where the “Dunnett’s test” has been used to
compare each experimental mean with the control mean (T plus Mtb/DC
Supe). This experiment is representative of three such experiments.1477 Heinzel et al.
if the antigen found within the supernatants could stabilize
cell-surface expression of HLA-E. For reference, FACS®
staining for cell surface expression HLA-E of the cell lines
used herein is provided (Fig. 2 a). The cell line T2 is TAP
deficient, and hence expresses little cell surface HLA. Incu-
bation of these cells overnight at 27 C facilitates the cell-
surface expression and possible loading of empty HLA-I
(36). Addition of the HLA-A2 leader peptide (VMAP-
RTLVL), in comparison to control peptide, stabilizes
HLA-E expression (MFI   32 vs. 19; Fig. 2 b); Similarly,
Mtb/DC-conditioned medium, in comparison to DC con-
trol supernatant, stabilized the cell-surface expression of
HLA-E (MFI   33 vs. 22; Fig. 2 c). Stabilization of HLA-E
was not observed at 37 C (unpublished data). Thus, these
data suggested that Mtb/DC supernatants could contain a
high-affinity HLA-E–binding activity capable of stabilizing
HLA-E.
We then sought to directly test the hypothesis that the
nonclassical T cell clones 23 and 29 are restricted by HLA-E.
Because T cells express HLA-E, and hence would poten-
tially be capable of self-presentation of preprocessed anti-
gen, we sought to define conditions where each T cell
would come in contact with a well-characterized APC. For
this purpose, we used the ability of the sensitive IFN- 
ELISPOT to detect small numbers of T cells. Here, 200–
250 nonclassical T cells were incubated with 20,000 APCs
transfected to express defined restriction molecules. In the
presence of Mtb/DC-conditioned media, the 721.221-
AEH cell line (which has been stably transfected to express
HLA-E along with the stabilizing HLA-A2 leader peptide;
reference 31) and to a lesser extent T2 were able to present
antigen to the nonclassical CD8  T cells 23 and 29, while
the 721.221 F, C1R-CD1a, C1R-CD1b, or C1R-CD1c
functioned far less efficiently as APC (Fig. 3). The ability of
each cell line to present Mtb/DC conditioned media cor-
related well with cell surface expression of HLA-E (Fig. 2
a), and was further corroborated by the observation that the
cell line 721.221 E, transfected to express HLA-E, but defi-
cient in cell surface expression by virtue of absence of HLA
leader peptide, failed to function as an APC (unpublished
data). Less than 10 spots were observed when T cells and
APC were coincubated in the presence of control DC su-
pernatant excluding the possibility that the presence of
HLA-E, or HLA-E stabilized by the HLA-A2 leader pep-
tide alone was sufficient to activate the clones (Fig. 3).
While compelling, interpretation of these data is compli-
cated by the fact that all of the cell lines tested express
HLA-E, with surface expression limited by the availability
of the HLA-Ia leader peptides. In contrast, HLA-E is not
present in the mouse. Thus, we asked whether or not the
Figure 2. Cell surface expression of HLA-E and stabili-
zation by Mtb/DC-conditioned media. (A) The cell lines
Daudi, T2, 721.221 F, 721.221 AEH, C1R-CD1a, LCL,
and human monocyte-derived DCs were assessed for cell
surface expression of HLA-E using the anti–HLA-E anti-
body 3D12 (shaded histogram). Isotype control staining is
shown in the white histogram. For reference, cell surface
expression of HLA-A2 and HLA-DR is shown on human
monocyte-derived DCs. (B) TAP-deficient T2 cells were
incubated overnight at 27 C with control DC conditioned
media in the presence of either the HLA-A2 leader peptide
VMAPRTLVL or control peptide AEMKTDAATL and
stained for cell surface expression of HLA-E. Results rep-
resent the mean of duplicate determinations. These data
are representative of two experiments.(C) TAP-deficient
T2 cells were incubated overnight at 27 C with either
control DC-conditioned media or Mtb/DC-conditioned
media and stained for cell surface expression of HLA-E.
Results represent the mean of duplicate determinations.
These data are representative of two experiments.1478 HLA-E and Host Response to TB
mouse phagocytic cell lines BM1 and J774 could process
and present Mtb-derived antigen in the context of HLA-E.
Initially, stable expression of human  2M was achieved by
retroviral transduction. These cells were then infected with
HLA-E expressing or control adenovirus (MOI    50;
HLA-E RAd270, reference 37, control RAd35, reference
38), and then infected with Mtb 1 d later. After overnight
infection with Mtb (H37Rv; MOI    2), the IFN- 
ELISPOT assay was used to assess the ability of the non-
classical T cell clones to recognize Mtb in the context of
HLA-E. Cell surface expression of HLA-E could be dem-
onstrated on the  2M-expressing cell lines via stabilization
with the HLA-A2 leader peptide (Fig. 4 a, MFI   22 vs.
9). Previously, we have found that a minority ( 1:50) of
Mtb-infected DCs are recognized by either classically or
nonclassically restricted CD8  T cells, and that recognition
is correlated with the degree of intracellular infection (un-
published data). As a result, we postulated that HLA-E–
dependent antigen processing and presentation would be
relatively inefficient in the context of the murine cell lines.
To this end, a saturating number of T cell clones (20,000)
were used to ensure maximum detection of Mtb-infected
APC.  Both HLA-E and Mtb were required for T cell–
dependent IFN-  release by the nonclassically restricted
clones (Fig. 4 b). The relatively modest number of Mtb-
specific spots observed likely reflects the limiting number of
functional APC in each well. As a control, the HLA-B44,
CFP10/Mtb11 specific T cell clone 1–1B demonstrated no
response to these cell lines in the presence or absence of Mtb.
The crystal structure of HLA-E has been solved, and it
has been suggested that the peptide-binding groove is
uniquely able to present a limited set of hydrophobic pep-
tides (30). We speculated, that the antigen presented by
HLA-E might be a hydrophobic peptide or protein associ-
ated with the mycobacterial cell wall. To test this hypothe-
sis, DCs were pulsed with partially-purified Mtb fractions.
In these experiments, a saturating number of T cells
(20,000) and APCs (20,000) were used to maximize the
sensitivity of the assay for the detection of the antigenic ac-
tivity. Neither secreted proteins, purified lipids from Mtb,
nor Mtb DNA could elicit T cell dependent release of
IFN-  (Fig. 5 a). In contrast, both the cell wall fraction,
and the lipoprotein-enriched TX-114 fraction were capa-
ble of sensitizing DC targets for T cell recognition. The re-
sponse seen was dependent on the concentration of antigen
added, confirming that neither T cells nor APCs were lim-
iting under these experimental conditions. Treatment of
the TX-114 fraction with the serine endopeptidase pro-
teinase K abolished the antigenic activity in a manner simi-
Figure 3. Preferential presentation of Mtb/DC-conditioned media by
HLA-E. 200 nonclassical T cell clones were coincubated overnight with
20,000 stably transfected cells in the presence of either Mtb/DC or DC
control conditioned media. IFN-  release was determined by ELISPOT.
Less than 10 ELISPOTS are observed with DC control media. Results
represent the mean of duplicate determinations. Error bars denote the
SEM. *P   0.05, where the “Dunnett’s test” has been used to compare
each experimental mean with the control mean (721.221 F). These data
are representative of three experiments.
Figure 4. Preferential presentation by mouse macrophage cell lines ex-
pressing HLA-E. The pBIB retroviral vector containing human  2m was
provided by S. Fling (Corixa Corp., Seattle, WA) and used to transduce
murine J774 and BM12 cell lines under blastocidin selection (reference
40) and cell surface expression of human  2m confirmed via FACS®. (A)
 2m-expressing J774 cells were infected with either control (Rad35) or
HLA-E (Rad270) adenovirus. After 24 h, cells were incubated overnight
at 27 C in the presence of HLA-A2 leader peptide VMAPRTLVL. Cell
surface expression of HLA-E was assessed using the anti–HLA-E antibody
3D12. These data are representative of two experiments. (B) Murine J774
and BM12 cell lines expressing human  2M were infected with either
control or HLA-E adenovirus, MOI   50:1. After 24 h, cells were in-
fected with Mtb (H37Rv, MOI   2). To ensure detection of Mtb-
infected cells, a saturating number (20,000) of T cells were added and after
18 h of coincubation IFN-  release assessed by ELISPOT. All data repre-
sent the mean of duplicate determinations. Error bars denote the SEM.
*P   0.05, where the “Dunnett’s test” has been used to compare each ex-
perimental mean with the control mean. These data are representative of
two experiments.1479 Heinzel et al.
lar to that shown for the Mtb/DC-conditioned media (un-
published data). Interestingly, treatment of the TX-114
fraction with pronase, a mixture of bacterial endo and exo
proteinases, resulted in augmented antigenic activity (Fig. 5
b). We speculate that this differential susceptibility to pro-
teolytic cleavage reflects a posttranslationally modified, and
hence partially protected peptide.
To determine whether or not this pronase fraction was
presented in an HLA-E–dependent fashion, stably trans-
fected APCs were tested for their ability to present Mtb-
derived antigen as described for Fig. 3. The Mtb-derived
antigenic activity could be preferentially presented by the
cell lines that express cell-surface HLA-E (721.221-AEH
and LCL; Fig. 5 c). Importantly, the NK target Daudi was
not recognized. Finally, while not HLA-E specific, we
have found antibodies to CD8 and pan-HLA I (W6/32)
capable of inhibiting the T cell–dependent recognition of
the antigenic fraction (unpublished data).
Discussion
Taken together, these data provide the first compelling
evidence that the nonclassical, Mtb-specific clones 23 and 29
recognize pathogen-derived antigen in the context of HLA-E,
and extends the function of this molecule beyond its known
role as an NK inhibitor through the interaction with the
NKG2A/CD94 heterodimer. It is very unlikely that T cell ac-
tivation is occurring through the NKG2A/CD94 heterodimer.
First, antibodies known to block NK recognition via HLA-E
or CD94 have proven ineffective in blocking T cell–dependent
recognition of Mtb-infected DCs (unpublished data). Addi-
tionally, HLA-E–deficient cell lines (Daudi), which serve as
NK targets through the lack of CD94/NKG2A inhibition, are
not recognized by the nonclassical T cells (Fig. 5 c). Instead, we
postulate that recognition of Mtb-derived antigen is occurring
through the TCR.
All of the human cell lines tested express HLA-E, with
cell surface expression limited by the availability of the
Figure 5. Presentation by HLA-E of lipid-enriched
antigen of Mtb. (A) 20,000 T cell clones were coincu-
bated with 20,000 DC in the presence of either man-
nose lipoarabinomannan (ManLAM), Triton X-114 li-
poprotein fraction (TX-114), CFPs, cell wall fraction
(CW), cell membrane fraction (MEM), cytosol fraction
(CYT), mycolylarabinogalactan peptidoglycan (mAGP),
or Mtb genomic DNA (gen. DNA) at the concentra-
tions indicated. After 18 h of coculture, IFN-  was
assessed by ELISPOT. These data are representative of
three experiments. (B) Using 20,000 nonclassical T cells
and 20,000 autologous DCs, antigens were tested at 10
 g/ml for T cell–dependent release of IFN-  by
ELISPOT. Error bars denote the SEM. *P    0.05,
where the “Dunnett’s test” has been used to compare
each experimental mean with the control mean (No
Antigen). (C) 250 T cells were coincubated with 20,000
APCs in the presence of 10  g/ml of pronase-treated
TX-114 antigen. IFN-  release is assessed by ELISPOT.
Results represent the mean of duplicate determinations.
Error bars denote the SEM. *P     0.05, where the
“Dunnett’s test” has been used to compare each experi-
mental mean with the control mean (721.221 F). These
data are representative of three experiments.1480 HLA-E and Host Response to TB
HLA-Ia leader peptides (C1R and 721.221). Thus, the
preferential recognition of the 721.221-AEH, LCL, DCs,
and to a lesser extent T2 cell lines may reflect the greater
cell-surface expression of HLA-E, with subsequent dis-
placement of the HLA-Ia peptide. Cell-surface stabilization
of HLA-E was not observed at 37 C.
Earlier studies demonstrated that nonclassically restricted
T cells comprised the majority of Mtb-specific CD8 T cells
in two latently infected subjects (9). However, whether
these cells are entirely HLA-E restricted, and whether they
recognize a common, or similar class of antigens remains to
be determined. The current data would support the hy-
pothesis that the antigen is a hydrophobic peptide, possibly
modified via either lipidation or glycosylation. This hy-
pothesis is further supported by the recent observation that
hydrophobic peptides can be presented in a proteasomal-
dependent, but TAP-independent pathway (39). By anal-
ogy with other HLA-Ib presentation pathways, it is attrac-
tive to speculate that the modifications represent unique
characteristics of Mtb or mycobacteria. Nonetheless, ad-
dressing these questions may have important implications
for the design of a vaccine capable of eliciting CD8  T cell
specific immunity.
In summary, this report is the first demonstration of rec-
ognition of a pathogen-derived antigen being presented in
the context of HLA-E. Three independent approaches
antigen to human CD8  T cells in this context. First, an-
tigenic activity found within conditioned Mtb/DC su-
pernatants was presented preferentially by the HLA-E–
expressing 721.221 AEH cell line. Furthermore, these
supernatants could stabilize the expression of HLA-E on
the TAP-deficient T2 cell line at 27 C. Second, murine
macrophage cell lines coexpressing human  2M and HLA-E
acquired the ability to present to the nonclassical T cells af-
ter infection with Mtb. Third, lipoprotein enriched, Mtb-
derived material could be presented in the context of
HLA-E. Thus, HLA-E should be included as an HLA-Ib
processing and presentation system.
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